Answer
Mavacamten selectively, allosterically and reversibly inhibits cardiac myosin, modulating how many myosin heads enter power-generating states to reduce (or normalise in hypertrophic cardiomyopathy) force-producing systolic and residual diastolic cross-bridge formation, while shifting myosin towards an energy-sparing but recruitable super-relaxed state.
Sources for this answer
- Mavacamten BMS 2.5 mg, 5 mg, 10 mg, 15 mg hard capsulesBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 6Document updated
Sources checked